PTGS2 and colorectal carcinoma: The COX-2 and EGFR pathways mutually enhance their pro-tumorigenic effects in different tumor types [12] and we have previously shown that the combined treatment of the anti-EGFR drug AEE788 and the specific COX-2 inhibitor celecoxib demonstrated enhanced anti-tumoral efficacy in CRC cells [13].